Leroy Bell, MD
Psychiatry · Baltimore, MDNPI 1568434181
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,138 of the $20,372 with a category attached, or 64.5%. 17 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 42.8% of the total. 2025 is the largest year on record at $9,175, 6.2 times the $1,488 reported in 2019. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 678 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$9K
- Johnson & Johnson$3K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $3K from 11 others
What the payments were for
- Speaking & faculty fees$6,65033%
- Food & beverage$13,13864%
- Education$5843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 79 | $8,727 |
| Johnson & Johnson | 113 | $2,583 |
| Neurocrine Biosciences, Inc. | 96 | $2,045 |
| Alkermes, Inc. | 61 | $1,295 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,281 |
| Otsuka America Pharmaceutical, Inc. | 61 | $1,129 |
| AbbVie(2 entities) | 82 | $934 |
| Vanda Pharmaceuticals Inc. | 32 | $741 |
| E.r. Squibb & Sons, L.L.C. | 24 | $550 |
| Lundbeck LLC | 18 | $352 |
| Indivior Inc. | 16 | $314 |
| Eisai Inc. | 13 | $241 |
| Noven Therapeutics, LLC | 4 | $58 |
| Luye Pharma (USA) Ltd. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$6,650
How this compares
$20,372 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 64 | $366,926 |
| Invega SustennaPaliperidone Palmitate | 114 | $320,793 |
| Invega HafyeraPaliperidone Palmitate | 15 | $267,228 |
| Invega TrinzaPaliperidone Palmitate | 33 | $253,186 |
| IngrezzaValbenazine Tosylate | 25 | $197,208 |
| Austedo XrDeutetrabenazine | 28 | $170,944 |
| Abilify MaintenaAripiprazole | 55 | $149,302 |
| AristadaAripiprazole Lauroxil | 16 | $61,633 |
| VraylarCariprazine Hcl | 29 | $42,179 |
| Fluphenazine Hcl | 112 | $26,836 |
| Clozapine | 250 | $25,072 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,510 |
| Tetrabenazine | 13 | $23,997 |
| CaplytaLumateperone Tosylate | 12 | $21,109 |
| Paliperidone ErPaliperidone | 52 | $20,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $2,583 | $573,979147 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Loxapine | $8,727 | $539,473111 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,045 | $197,20825 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,129 | $149,30255 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,295 | $86,14331 claims |
| AbbVieVraylar | $934 | $42,17929 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,281 | $21,10912 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $741 | $16,69922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.